• Something wrong with this record ?

Vaccination with human papillomavirus type 16-derived peptides using a tattoo device

Dana Pokorná, Ingrid Poláková, Martina Kindlová, Martina Dušková, Viera Ludvíková, Pavel Gabriel, Luďa Kutinová, Martin Müller, Michal Šmahel

. 2009 ; 27 (27) : 3519-3529.

Language English Country Netherlands

Document type Research Support, Non-U.S. Gov't

Grant support
NR9246 MZ0 CEP Register

Digital library NLK
Full text - Article
Source

E-resources Online Full text

NLK ProQuest Central from 2002-01-01 to 2 months ago
Nursing & Allied Health Database (ProQuest) from 2002-01-01 to 2 months ago
Health & Medicine (ProQuest) from 2002-01-01 to 2 months ago
Family Health Database (ProQuest) from 2002-01-01 to 2 months ago
Health Management Database (ProQuest) from 2002-01-01 to 2 months ago
Public Health Database (ProQuest) from 2002-01-01 to 2 months ago
ScienceDirect (archiv) from 1993-01-01 to 2009-12-31

Tattooing has been shown to be very efficient at inducing immunity by vaccination with DNA vaccines. In this study, we examined the usability of tattooing for delivery of peptide vaccines. We compared tattooing with subcutaneous (s.c.) needle injection using peptides derived from human papillomavirus type 16 (HPV16) proteins. We observed that higher peptide-specific immune responses were elicited after vaccination with the simple peptides (E7(44-62) and E7(49-57)) and keyhole limpet hemocyanin-(KLH)-conjugated peptides (E7(49-57), L2(18-38) and L2(108-120)) with a tattoo device compared to s.c. inoculation. The administration of the synthetic oligonucleotide containing immunostimulatory CpG motifs (ODN1826) enhanced the immune responses developed after s.c. injection of some peptides (E7(44-62), KLH-conjugated L2(18-38) and L2(108-120)) to levels close to or even comparable to those after tattoo delivery of identical peptides with ODN1826. The highest efficacy of tattooing was observed in combination with ODN1826 for the vaccination with the less immunogenic E6(48-57) peptide and KLH-conjugated and non-conjugated E7(49-57) peptides which form the visible aggregates that could negatively influence the development of immune responses after s.c. injection but probably not after tattooing. In summary, we first evidenced that tattoo administration of peptide vaccines that might be useful in some cases efficiently induced both humoral and cell-mediated immune responses.

References provided by Crossref.org

000      
03429naa 2200517 a 4500
001      
bmc11017088
003      
CZ-PrNML
005      
20221005134725.0
008      
110629s2009 ne e eng||
009      
AR
024    7_
$a 10.1016/j.vaccine.2009.03.073 $2 doi
035    __
$a (PubMed)19464530
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Pokorná, Dana $7 xx0063975 $u Department of Experimental Virology, Institute of Hematology and Blood Transfusion, Prague, Czech Republic
245    10
$a Vaccination with human papillomavirus type 16-derived peptides using a tattoo device / $c Dana Pokorná, Ingrid Poláková, Martina Kindlová, Martina Dušková, Viera Ludvíková, Pavel Gabriel, Luďa Kutinová, Martin Müller, Michal Šmahel
314    __
$a Institute of Hematology and Blood Transfusion, Department of Experimental Virology, U Nemocnice 1, 12820 Prague 2, Czech Republic. danap@uhkt.cz
520    9_
$a Tattooing has been shown to be very efficient at inducing immunity by vaccination with DNA vaccines. In this study, we examined the usability of tattooing for delivery of peptide vaccines. We compared tattooing with subcutaneous (s.c.) needle injection using peptides derived from human papillomavirus type 16 (HPV16) proteins. We observed that higher peptide-specific immune responses were elicited after vaccination with the simple peptides (E7(44-62) and E7(49-57)) and keyhole limpet hemocyanin-(KLH)-conjugated peptides (E7(49-57), L2(18-38) and L2(108-120)) with a tattoo device compared to s.c. inoculation. The administration of the synthetic oligonucleotide containing immunostimulatory CpG motifs (ODN1826) enhanced the immune responses developed after s.c. injection of some peptides (E7(44-62), KLH-conjugated L2(18-38) and L2(108-120)) to levels close to or even comparable to those after tattoo delivery of identical peptides with ODN1826. The highest efficacy of tattooing was observed in combination with ODN1826 for the vaccination with the less immunogenic E6(48-57) peptide and KLH-conjugated and non-conjugated E7(49-57) peptides which form the visible aggregates that could negatively influence the development of immune responses after s.c. injection but probably not after tattooing. In summary, we first evidenced that tattoo administration of peptide vaccines that might be useful in some cases efficiently induced both humoral and cell-mediated immune responses.
590    __
$a bohemika - dle Pubmed
650    _2
$a sekvence aminokyselin $7 D000595
650    _2
$a zvířata $7 D000818
650    _2
$a virové plášťové proteiny $x imunologie $7 D036022
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a hemokyanin $x imunologie $7 D006433
650    _2
$a lidský papilomavirus 16 $x imunologie $7 D052162
650    _2
$a myši $7 D051379
650    _2
$a myši inbrední C57BL $7 D008810
650    _2
$a molekulární sekvence - údaje $7 D008969
650    _2
$a onkogenní proteiny virové $x imunologie $7 D009856
650    _2
$a Papillomavirus E7 - proteiny $7 D050725
650    _2
$a vakcíny proti papilomavirům $x imunologie $7 D053918
650    _2
$a peptidové fragmenty $7 D010446
650    _2
$a represorové proteiny $x imunologie $7 D012097
650    _2
$a cytotoxické T-lymfocyty $x imunologie $7 D013602
650    _2
$a tetování $7 D013653
650    _2
$a vakcinace $7 D014611
650    _2
$a DNA vakcíny $x imunologie $7 D019444
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Poláková, Ingrid $7 xx0139787 $u Department of Experimental Virology, Institute of Hematology and Blood Transfusion, Prague, Czech Republic
700    1#
$a Kindlová, Martina. $7 _AN066491 $u Department of Experimental Virology, Institute of Hematology and Blood Transfusion, Prague, Czech Republic
700    1_
$a Dušková, Martina $7 xx0127833 $u Department of Experimental Virology, Institute of Hematology and Blood Transfusion, Prague, Czech Republic
700    1_
$a Ludvíková, Viera, $7 xx0078797 $u Department of Experimental Virology, Institute of Hematology and Blood Transfusion, Prague, Czech Republic $d 1954-
700    1_
$a Gabriel, Pavel $7 xx0139712 $u Department of Experimental Virology, Institute of Hematology and Blood Transfusion, Prague, Czech Republic
700    1_
$a Kutinová, Luďa, $7 xx0119195 $u Department of Experimental Virology, Institute of Hematology and Blood Transfusion, Prague, Czech Republic $d 1942-
700    1_
$a Müller, M $b German Cancer Research Center, Research Group of Tumorvirus-Specific Vaccination Strategies, Heidelberg, Germany
700    1_
$a Šmahel, Michal $7 xx0060364 $u Department of Experimental Virology, Institute of Hematology and Blood Transfusion, Prague, Czech Republic
773    0_
$t Vaccine $w MED00004631 $g Roč. 27, č. 27 (2009), s. 3519-3529 $x 0264-410X
910    __
$a ABA008 $b x $y 2 $z 0
990    __
$a 20110720100443 $b ABA008
991    __
$a 20221005134720 $b ABA008
999    __
$a ok $b bmc $g 864156 $s 726883
BAS    __
$a 3
BMC    __
$a 2009 $x MED00004631 $b 27 $c 27 $d 3519-3529 $i 0264-410X $m Vaccine $n Vaccine
GRA    __
$a NR9246 $p MZ0
LZP    __
$a 2011-3B09/BBjvme

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...